177 related articles for article (PubMed ID: 21928258)
21. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab).
Ehmann D; García R
Can J Ophthalmol; 2010 Feb; 45(1):36-40. PubMed ID: 20130708
[TBL] [Abstract][Full Text] [Related]
22. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O
Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600
[TBL] [Abstract][Full Text] [Related]
23. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
24. Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation.
Freund KB; Klais CM; Eandi CM; Ober MD; Goldberg DE; Sorenson JA; Yannuzzi LA
Arch Ophthalmol; 2006 Apr; 124(4):487-92. PubMed ID: 16606873
[TBL] [Abstract][Full Text] [Related]
25. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization.
Degenring RF; Jonas JB
Acta Ophthalmol Scand; 2005 Oct; 83(5):621. PubMed ID: 16188006
[No Abstract] [Full Text] [Related]
26. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
27. Anatomical and visual outcome of retinal angiomatous proliferation treated with photodynamic therapy and intravitreal triamcinolone.
van de Moere A; Kak R; Sandhu SS; Talks SJ
Am J Ophthalmol; 2007 Apr; 143(4):701-4. PubMed ID: 17386286
[TBL] [Abstract][Full Text] [Related]
28. Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits.
Kim RY; Chung SK; Kim MS; Ra H
Cornea; 2016 Dec; 35(12):1615-1620. PubMed ID: 27684458
[TBL] [Abstract][Full Text] [Related]
29. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
30. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
Ergun E; Maár N; Ansari-Shahrezaei S; Wimpissinger B; Krepler K; Wedrich A; Stur M
Am J Ophthalmol; 2006 Jul; 142(1):10-16. PubMed ID: 16815246
[TBL] [Abstract][Full Text] [Related]
31. Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration.
Datseris I; Kontadakis GA; Diamanti R; Datseris I; Pallikaris IG; Theodossiadis P; Tsilimbaris MK
Semin Ophthalmol; 2015 Mar; 30(2):112-7. PubMed ID: 24117412
[TBL] [Abstract][Full Text] [Related]
32. Photodynamic therapy of corneal neovascularization with verteporfin.
Fossarello M; Peiretti E; Zucca I; Serra A
Cornea; 2003 Jul; 22(5):485-8. PubMed ID: 12827058
[TBL] [Abstract][Full Text] [Related]
33. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis.
Smithen LM; Spaide RF
Am J Ophthalmol; 2004 Nov; 138(5):884-5. PubMed ID: 15531339
[TBL] [Abstract][Full Text] [Related]
34. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
[TBL] [Abstract][Full Text] [Related]
36. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
[TBL] [Abstract][Full Text] [Related]
37. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Kano M; Iida T
Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
[TBL] [Abstract][Full Text] [Related]
38. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
39. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
[TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy with verteporfin for corneal neovascularization.
Yoon KC; You IC; Kang IS; Im SK; Ahn JK; Park YG; Ahn KY
Am J Ophthalmol; 2007 Sep; 144(3):390-395. PubMed ID: 17631268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
